Monitor quarterly filings for actual share issuance volumes under the ATM to gauge the pace of dilution. Forward sale agreements may delay dilution recognition but represent future equity exposure. The company has already issued $2.73 billion under this program, indicating ongoing capital needs.
Price Chart
Executive Summary
Ameren Corp filed a prospectus supplement for an at-the-market (ATM) equity offering of up to $2.27 billion of common stock under its existing $5 billion sales agreement, of which $2.73 billion has already been sold. Proceeds will be used for general corporate purposes including repayment of short-term debt. The offering dilutes existing shareholders by approximately 7–8% at the current stock price and will be executed over time through multiple agents and may involve forward sale agreements.
Key Facts
- Up to $2,266,700,000 of common stock may be sold under the ATM program; $2,733,300,000 has already been sold under the same $5 billion sales agreement.
- Sales agents include Barclays, BofA Securities, Goldman Sachs, J.P. Morgan, Mizuho, Morgan Stanley, MUFG, RBC Capital Markets, and Wells Fargo Securities.
- Commissions of up to 2% of gross sales price per share will be paid to sales agents.
- Proceeds are for general corporate purposes, which may include repayment of short-term debt.
- The offering may utilize forward sale agreements, where Ameren does not initially receive proceeds and future dilution may occur upon physical settlement.
- Last reported sale price of AEE on August 3, 2026 was $109.50 per share.
- At that price, $2.27 billion represents approximately 20.7 million shares, or about 7.5% of the 276.8 million shares outstanding as of July 30, 2026.
Financial Impact
Up to $2.27 billion in common stock issued, representing approximately 20.7 million new shares (7.5% dilution) at $109.50 per share.
Risk Factors
- Dilution to EPS and return on equity from increased share count.
- Potential downward pressure on stock price from continuous ATM equity sales.
- Forward sale agreement risks: forced settlement or termination could accelerate dilution or result in cash obligations.
- Proceeds used for short-term debt repayment may not support earnings growth.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-090479 |
| Document: tm2621667d3_ex-filingfees.htm | 0001104659-26-090479 |
| Document: 0001104659-26-090479-index-headers.html | 0001104659-26-090479 |
| Document: 0001104659-26-090479-index.html | 0001104659-26-090479 |
| Document: 0001104659-26-090479.txt | 0001104659-26-090479 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | 8-K | $107.16 $101.66 | ▼ −5.13% | ▼ −6.45% | $99.94 (−6.74%) |
Aug 17, 2026 6w ago | Press Release | $109.67 $103.75 | ▼ −5.40% | ▼ −4.41% | $99.94 (−8.87%) |
Aug 14, 2026 7w ago | Press Release | $109.74 $103.97 | ▼ −5.26% | ▼ −3.27% | $99.94 (−8.93%) |
Aug 4, 2026 8w ago | 424B5 | $108.95 $105.89 | ▲ +2.81% | ▲ +2.21% | $99.94 (+8.27%) |
Aug 4, 2026 8w ago | S-3ASR | $109.44 $106.09 | ▼ −3.06% | ▼ −1.82% | $99.94 (−8.68%) |
Aug 4, 2026 8w ago | Institutional Cluster | $109.44 $106.09 | ▼ −3.06% | ▼ −1.82% | $99.94 (−8.68%) |
Jul 30, 2026 9w ago | Press Release | $109.61 $106.12 | ▼ −3.18% | ▼ −6.17% | $99.94 (−8.82%) |
Jul 9, 2026 12w ago | Press Release | $112.94 $108.84 | ▼ −3.63% | ▼ −6.06% | $99.94 (−11.51%) |
Jun 29, 2026 13w ago | 8-K | $114.59 $113.78 | ▼ −0.71% | ▼ −0.43% | $99.94 (−12.78%) |
Jun 26, 2026 13w ago | 8-K | $114.59 $113.78 | ▼ −0.71% | ▼ −0.43% | $99.94 (−12.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access